Plant Name: Albizia julibrissin
Taxonomic Information:
Plant ID: NPO12181
Plant Latin Name: Albizia julibrissin
Taxonomy Genus: Albizia
Taxonomy Family: Fabaceae
Plant External Links:
NCBI TaxonomyDB:
3813
Plant-of-the-World-Online:
473275-1
Used in Medicines:
Country/Region:
South Korea; IndiaTraditional Medicine System:
Indian FolkMedicinal Functions:
Analgesic; Anthelmintic; Carminative; Digestive; Diuretic; Oxytoxic; Plaster; Plaster; Sedative; Stimulant; Tonic; Vulnerary
Geographical Distribution:
Turkey; Bangladesh; Nepal; Peru; Argentina; Turkmenistan; Iran; Russia; China; Iraq; Ukraine; United States; South Korea; Pakistan; Myanmar; South Africa; Cyprus; India; Uzbekistan; Japan; Taiwan; Tajikistan
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| SMO; | |
| ADRB3; FFAR1; FFAR4; ADRA2C; ADRA2A; ADRA2B; DRD2; | |
| OPRD1; NPSR1; | |
| ACHE; | |
| TDP1; BLM; CDA; ALOX12; AKR1B1; HSD17B2; HSD17B10; NOX4; ALOX15; HSD17B1; TNKS; TNKS2; APEX1; POLB; | |
| AURKB; AXL; FLT3; CDK1; MAPK1; PIM1; MET; KDR; IGF1R; CSNK2A1; | |
| CA2; CA12; CA9; CA14; CA7; CA4; | |
| ESR2; | |
| TYR; | |
| KDM4E; | |
| MMP12; | |
| AHR; HIF1A; TP53; | |
| FUT7; | |
| LMNA; FABP3; SHH; FABP4; MAPT; THPO; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | CDA | Cytidine deaminase | P32320 | CHEMBL4502 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | OPRD1 | Delta opioid receptor | P41143 | CHEMBL236 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Small molecule receptor (family A GPCR) | ADRB3 | Beta-3 adrenergic receptor | P13945 | CHEMBL246 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
| Small molecule receptor (family A GPCR) | DRD2 | Dopamine D2 receptor | P14416 | CHEMBL217 |
| Smoothened receptor (frizzled family GPCR) | SMO | Smoothened homolog | Q99835 | CHEMBL5971 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | SHH | Sonic hedgehog protein | Q15465 | CHEMBL5602 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 3.771E-12 | 5.866E-09 | CA12, CA14, CA2, CA4, CA7, CA9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 9.071E-11 | 9.406E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP3A4, NOX4 |
| BP | GO:0009987; cellular process | GO:0071880; adenylate cyclase-activating adrenergic receptor signaling pathway | 3.972E-09 | 1.880E-06 | ADRA2A, ADRA2B, ADRA2C, ADRB3, DRD2 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 4.955E-09 | 2.118E-06 | CA12, CA14, CA2, CA4, CA7, CA9 |
| MF | GO:0005488; binding | GO:0051379; epinephrine binding | 6.240E-09 | 2.366E-06 | ADRA2A, ADRA2B, ADRA2C, ADRB3 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 8.557E-09 | 2.911E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.863E-08 | 5.558E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 2.997E-08 | 8.260E-06 | ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.773E-08 | 1.002E-05 | ALOX12, ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 5.011E-08 | 1.269E-05 | AHR, CSNK2A1, HIF1A, KDR, MAPT |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 9.291E-08 | 2.175E-05 | CA12, CA2, CA4, CA7, CA9 |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 1.196E-07 | 2.578E-05 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 1.196E-07 | 2.578E-05 | ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.196E-07 | 2.578E-05 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.542E-07 | 3.259E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP3A4, NOX4 |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 2.077E-07 | 4.227E-05 | AURKB, MAPK1, TNKS, TNKS2 |
| BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 3.127E-07 | 5.819E-05 | AXL, CA2, CA9, CSNK2A1, CYP1A1, CYP1A2, FABP3, FFAR1, FLT3, HSD17B2, SMO, TP53, TYR |
| BP | GO:0008283; cell proliferation | GO:0002052; positive regulation of neuroblast proliferation | 4.199E-07 | 7.683E-05 | DRD2, HIF1A, SHH, SMO |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 5.174E-07 | 9.235E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 5.953E-07 | 1.005E-04 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 1.380E-06 | 1.939E-04 | AKR1B1, APEX1, AXL, CDK1, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0010700; negative regulation of norepinephrine secretion | 1.659E-06 | 2.203E-04 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0009987; cellular process | GO:0045744; negative regulation of G-protein coupled receptor protein signaling pathway | 2.657E-06 | 3.325E-04 | ADRA2A, ADRB3, DRD2, MET |
| BP | GO:0065007; biological regulation | GO:0032212; positive regulation of telomere maintenance via telomerase | 3.888E-06 | 4.626E-04 | AURKB, MAPK1, TNKS, TNKS2 |
| MF | Unclassified; | GO:0004872; receptor activity | 4.038E-06 | 4.779E-04 | ADRA2A, ADRA2B, ADRA2C, ADRB3, AHR, AXL, DRD2, ESR2, FFAR1, FFAR4, FLT3, IGF1R, KDR, MET, NPSR1, OPRD1, SMO |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 6.460E-06 | 7.141E-04 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 6.460E-06 | 7.141E-04 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 7.419E-06 | 8.078E-04 | BLM, CA12, CA2, CA4, CA7, CA9, CDA, ESR2, MMP12, SHH, TNKS, TP53 |
| BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 8.380E-06 | 8.901E-04 | CYP19A1, HSD17B1, HSD17B2 |
| BP | GO:0040011; locomotion | GO:0030335; positive regulation of cell migration | 9.581E-06 | 9.889E-04 | ADRA2A, ALOX12, HIF1A, IGF1R, KDR, MAPK1, MET, NOX4, TP53 |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 9.810E-06 | 9.889E-04 | APEX1, POLB |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 9.810E-06 | 9.889E-04 | ALOX12, ALOX15 |
| BP | GO:0008152; metabolic process | GO:0019858; cytosine metabolic process | 9.810E-06 | 9.889E-04 | CDA, MAPK1 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 9.810E-06 | 9.889E-04 | ALOX12, ALOX15 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 1.397E-05 | 1.343E-03 | APEX1, BLM, CYP1A1, CYP1B1, FLT3, MAPK1, NOX4, SMO |
| BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 2.119E-05 | 1.870E-03 | ACHE, ALOX15, CDK1, CYP1A1, DRD2, TP53 |
| MF | GO:0005488; binding | GO:0031690; adrenergic receptor binding | 2.364E-05 | 2.043E-03 | ADRA2A, ADRA2C, ADRB3 |
| BP | GO:0009987; cellular process | GO:0030168; platelet activation | 2.523E-05 | 2.163E-03 | ADRA2A, ADRA2B, ADRA2C, AXL, MAPK1 |
| BP | GO:0009987; cellular process | GO:0007228; positive regulation of hh target transcription factor activity | 2.937E-05 | 2.432E-03 | SHH, SMO |
| BP | GO:0032502; developmental process | GO:0003140; determination of left/right asymmetry in lateral mesoderm | 2.937E-05 | 2.432E-03 | SHH, SMO |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.937E-05 | 2.432E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 2.937E-05 | 2.432E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 2.937E-05 | 2.432E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 2.937E-05 | 2.432E-03 | ALOX12, ALOX15 |
| BP | GO:0065007; biological regulation | GO:0048872; homeostasis of number of cells | 3.258E-05 | 2.657E-03 | AXL, FLT3, HIF1A, POLB, SMO |
| BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 3.530E-05 | 2.842E-03 | AURKB, CSNK2A1, FLT3, IGF1R, KDR, PIM1 |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 3.632E-05 | 2.876E-03 | ALOX15, DRD2, FFAR4, KDR, NOX4, THPO |
| BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 3.787E-05 | 2.987E-03 | ADRA2A, AKR1B1, APEX1, CA2, CA9, CSNK2A1, CYP1A2, FABP3, FFAR4, FLT3 |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 3.827E-05 | 3.009E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 5.073E-05 | 3.823E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 5.862E-05 | 4.255E-03 | TNKS, TNKS2 |
| BP | GO:0023052; signaling | GO:0021938; smoothened signaling pathway involved in regulation of cerebellar granule cell precursor cell proliferation | 5.862E-05 | 4.255E-03 | SHH, SMO |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 5.862E-05 | 4.255E-03 | CYP1A1, CYP1A2 |
| BP | GO:0032501; multicellular organismal process | GO:0040014; regulation of multicellular organism growth | 5.945E-05 | 4.272E-03 | ADRB3, DRD2, SMO, TNKS2 |
| MF | GO:0005488; binding | GO:0003684; damaged DNA binding | 5.945E-05 | 4.272E-03 | APEX1, BLM, POLB, TP53 |
| CC | GO:0044464; cell part | GO:0032838; plasma membrane bounded cell projection cytoplasm | 5.945E-05 | 4.272E-03 | AKR1B1, HIF1A, MAPK1, MAPT |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 7.398E-05 | 5.230E-03 | CYP19A1, CYP1A2, CYP3A4 |
| MF | GO:0005488; binding | GO:0005504; fatty acid binding | 8.304E-05 | 5.754E-03 | FABP3, FABP4, FFAR4 |
| BP | GO:0008152; metabolic process | GO:0008209; androgen metabolic process | 9.280E-05 | 6.354E-03 | CYP19A1, CYP3A4, SHH |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 9.743E-05 | 6.473E-03 | AXL, CDK1, CSNK2A1, FLT3 |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 9.750E-05 | 6.473E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 9.750E-05 | 6.473E-03 | CYP1A1, CYP3A4 |
| MF | GO:0005488; binding | GO:0051380; norepinephrine binding | 9.750E-05 | 6.473E-03 | ADRA2A, ADRB3 |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 9.853E-05 | 6.521E-03 | ADRA2A, ADRA2B, ADRA2C, ADRB3, AXL, DRD2, FFAR1, FFAR4, FLT3, IGF1R, KDR, MET, NPSR1, OPRD1 |
| BP | GO:0009987; cellular process | GO:0051262; protein tetramerization | 1.007E-04 | 6.623E-03 | ACHE, CDA, HSD17B10, IGF1R, TP53 |
| BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 1.078E-04 | 6.987E-03 | CDK1, CSNK2A1, MAPK1, TNKS |
| BP | GO:0050896; response to stimulus | GO:0010039; response to iron ion | 1.265E-04 | 8.053E-03 | CYP1A1, DRD2, HIF1A |
| BP | GO:0065007; biological regulation | GO:0051100; negative regulation of binding | 1.292E-04 | 8.176E-03 | ADRB3, AURKB, MET, SMO, TNKS |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 1.460E-04 | 9.029E-03 | CYP1A1, CYP3A4 |
| MF | GO:0005488; binding | GO:0046982; protein heterodimerization activity | 1.615E-04 | 9.767E-03 | ADRA2A, ADRA2C, AHR, AXL, DRD2, HIF1A, TP53, TYR |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 7.538E-12 | 1.184E-09 | CA12, CA2, CA4, CA7, CA9, CA14 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 4.583E-10 | 3.597E-08 | HSD17B1, CYP1A2, HSD17B2, CYP1A1, CYP1B1, CYP3A4, CYP19A1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 8.954E-09 | 4.686E-07 | HSD17B1, HSD17B2, CYP1A1, CYP1B1, CYP19A1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 2.745E-06 | 6.416E-05 | SMO, KDR, MAPK1, TP53, HIF1A, MET, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 1.865E-06 | 5.856E-05 | FLT3, MAPK1, TP53, MET, HIF1A |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 2.860E-06 | 6.416E-05 | CYP2C9, CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.757E-06 | 5.856E-05 | CYP2C9, CYP1A2, ALOX15, CYP3A4 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.644E-05 | 2.580E-04 | CDA, ALOX15, AKR1B1, ALOX12, CYP3A4, TYR, CYP19A1, HSD17B10, CYP2C9, FUT7, HSD17B1, HSD17B2, CYP1A2, CYP1A1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 1.176E-05 | 2.052E-04 | OPRD1, ADRB3, MAPK1, ADRA2C, ADRA2B, ADRA2A |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 2.638E-05 | 3.765E-04 | SHH, SMO, FLT3, MAPK1, HIF1A, MET, TP53, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 5.088E-06 | 9.986E-05 | CYP2C9, CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 6.531E-05 | 7.887E-04 | MAPK1, TP53, MET, IGF1R |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 4.613E-05 | 6.036E-04 | CYP2C9, CYP1A2, CYP1A1, CYP3A4 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 7.681E-05 | 8.614E-04 | CSNK2A1, MAPK1, MET, IGF1R |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.960E-04 | 2.052E-03 | OPRD1, ADRB3, ADRA2C, DRD2, ADRA2B, ADRA2A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 4.589E-04 | 4.003E-03 | KDR, MAPK1, DRD2, MET, IGF1R |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 3.803E-04 | 3.512E-03 | CYP2C9, ALOX15, MAPK1, ALOX12 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 2.461E-04 | 2.415E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 7.025E-04 | 5.515E-03 | FLT3, PIM1, MAPK1 |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 1.031E-03 | 7.355E-03 | MAPK1, TP53, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05217 | Basal cell carcinoma | 6.326E-04 | 5.227E-03 | SHH, SMO, TP53 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 8.983E-04 | 6.716E-03 | CYP2C9, ALOX15, ALOX12 |
| 09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 1.077E-03 | 7.355E-03 | MAPK1, MET, HIF1A |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.226E-03 | 8.018E-03 | CYP2C9, CYP1A2, CYP3A4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | ADRB3; DRD2; OPRD1; |
| I00-I99: Diseases of the circulatory system | Maintain blood pressure in hypotensive states | I10 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD2; |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; TYR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| NA: NA | Malignant essential hypertension | NA | DRD2; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; CA9; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | ADRB3; OPRD1; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | OPRD1; |
| NA: NA | HIV infections | NA | AHR; |
| NA: NA | False perceptions | NA | DRD2; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | OPRD1; AKR1B1; TYR; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | DRD2; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; ADRB3; DRD2; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | DRD2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; DRD2; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; ADRA2C; ADRB3; DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Moderate-to-severe pain | R52, G89 | OPRD1; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C; |
| NA: NA | Corneal vascularity | NA | DRD2; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | ADRB3; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; CSNK2A1; FLT3; ACHE; HIF1A; MAPK1; TP53; CA9; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; TP53; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| I00-I99: Diseases of the circulatory system | Pulmonary hypertension | I27.0, I27.2 | DRD2; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Idiopathic thrombocytopenic purpura | D69.3 | DRD2; |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | ADRB3; OPRD1; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | ADRB3; DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; ACHE; DRD2; OPRD1; |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; MAPT; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C; DRD2; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | ADRB3; FFAR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2B; ADRA2C; DRD2; OPRD1; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Advanced stage Parkinson's disease | F02.3, G20 | DRD2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| NA: NA | Vomiting | NA | DRD2; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; ADRA2C; DRD2; MAPT; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | DRD2; |
| NA: NA | Chronic diarrhea associated with inflammatory bowel disease | NA | OPRD1; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD2; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; |
| NA: NA | Itching | NA | DRD2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A; DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | ADRB3; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | DRD2; |
| I00-I99: Diseases of the circulatory system | Cardiotonic | I50 | DRD2; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; HIF1A; MAPK1; CDA; TP53; CA9; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | OPRD1; |
| NA: NA | Acute nonspecific diarrhea | NA | OPRD1; |
| J00-J99: Diseases of the respiratory system | Bronchitis | J20-J21, J42 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Carcinoid syndrome | E34.0 | DRD2; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| NA: NA | Schizoaffective disorders | NA | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; DRD2; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; TP53; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; DRD2; CYP19A1; CA9; |
| N00-N99: Diseases of the genitourinary system | Bladder disease | N30-N32 | OPRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychosis | F20-F29 | DRD2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD2; |
| NA: NA | Edema | NA | CA2; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| NA: NA | Benign prostatic hypertrophy | NA | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | DRD2; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | ADRA2C; ADRB3; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
| NA: NA | GIST | NA | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; ADRA2C; ADRB3; DRD2; AKR1B1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Acromegaly | E22.0 | DRD2; |
| NA: NA | Malignant phaeochromocytoma | NA | DRD2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Postpartum haemorrhage | O72 | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADRA2B; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; ADRA2C; |
| K00-K95: Diseases of the digestive system | Diarrhea-predominant IBS | K58.0 | OPRD1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperprolactinemia | E22.1 | DRD2; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C; ADRB3; DRD2; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ADRB3; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | OPRD1; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADRA2C; |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; AKR1B1; TP53; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | ADRB3; AKR1B1; FFAR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | ADRA2C; |
| K00-K95: Diseases of the digestive system | Dermal necrosis | K05 | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Depressive fatigue | R53.82 | DRD2; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; DRD2; |
| NA: NA | Inflammatory diseases | NA | DRD2; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; ADRA2A; ADRA2C; DRD2; OPRD1; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | DRD2; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| I00-I99: Diseases of the circulatory system | Ischemic heart diseases | I20-I25 | OPRD1; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; TP53; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| K00-K95: Diseases of the digestive system | Gastrointestinal problems | K30-K31, Q40-Q41 | DRD2; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; ADRA2C; |
| NA: NA | Peripheral vasoconstriction | NA | DRD2; |
| H00-H59: Diseases of the eye and adnexa | Ophthalmic disease | H00-H59 | DRD2; |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; ADRA2C; |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| NA: NA | Hyperaemia | NA | DRD2; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
